J Rosenstock1, P Hollander2, A Bhargava3, L L Ilag4, R K Pollom4, J S Zielonka4, W J Huster4, M J Prince4. 1. Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX, USA. 2. Baylor Endocrine Center, Dallas, TX, USA. 3. Iowa Diabetes and Endocrinology Research Center, Des Moines, IA, USA. 4. Eli Lilly and Company, Indianapolis, IN, USA.
Abstract
AIMS: To compare the efficacy and safety of LY2963016 insulin glargine (LY IGlar) and the reference product (Lantus(®)) insulin glargine (IGlar) in combination with oral antihyperglycaemic medications in patients with type 2 diabetes (T2D). METHODS: This phase III, randomized, double-blind, 24-week study enrolled patients with T2D who were insulin-naïve [glycated haemoglobin (HbA1c) ≥7 and ≤11.0%] or previously on IGlar (HbA1c ≤11%) and treated with ≥2 oral antihyperglycaemic medications. Patients were randomized to receive once-daily LY IGlar (n = 376) or IGlar (n = 380) for 24 weeks. The primary efficacy outcome was to test the non-inferiority (0.4% and then 0.3% margin) of LY IGlar to IGlar, as measured by change in HbA1c from baseline to 24 weeks. RESULTS: Both treatment groups had similar and significant (p < 0.001) within-group decreases in mean HbA1c values from baseline. LY IGlar met non-inferiority criteria compared with IGlar for change in HbA1c from baseline [-1.29 vs -1.34%; respectively, least-squares mean difference 0.052% (95% confidence interval -0.070 to 0.175); p > 0.05]. There were no treatment differences (p > 0.05) in fasting plasma glucose, proportion of patients reaching HbA1c <7% or insulin dose at 24 weeks. Adverse events, allergic reactions, weight change, hypoglycaemia and insulin antibodies were similar between treatment groups. Similar findings were observed in patients who were insulin-naïve or previously treated with IGlar at baseline. CONCLUSIONS: Both LY IGlar and IGlar, when used in combination with oral antihyperglycaemic medications, provided effective and similar glucose control with similar safety profiles in patients with T2D.
RCT Entities:
AIMS: To compare the efficacy and safety of LY2963016insulinglargine (LY IGlar) and the reference product (Lantus(®)) insulinglargine (IGlar) in combination with oral antihyperglycaemic medications in patients with type 2 diabetes (T2D). METHODS: This phase III, randomized, double-blind, 24-week study enrolled patients with T2D who were insulin-naïve [glycated haemoglobin (HbA1c) ≥7 and ≤11.0%] or previously on IGlar (HbA1c ≤11%) and treated with ≥2 oral antihyperglycaemic medications. Patients were randomized to receive once-daily LY IGlar (n = 376) or IGlar (n = 380) for 24 weeks. The primary efficacy outcome was to test the non-inferiority (0.4% and then 0.3% margin) of LY IGlar to IGlar, as measured by change in HbA1c from baseline to 24 weeks. RESULTS: Both treatment groups had similar and significant (p < 0.001) within-group decreases in mean HbA1c values from baseline. LY IGlar met non-inferiority criteria compared with IGlar for change in HbA1c from baseline [-1.29 vs -1.34%; respectively, least-squares mean difference 0.052% (95% confidence interval -0.070 to 0.175); p > 0.05]. There were no treatment differences (p > 0.05) in fasting plasma glucose, proportion of patients reaching HbA1c <7% or insulin dose at 24 weeks. Adverse events, allergic reactions, weight change, hypoglycaemia and insulin antibodies were similar between treatment groups. Similar findings were observed in patients who were insulin-naïve or previously treated with IGlar at baseline. CONCLUSIONS: Both LY IGlar and IGlar, when used in combination with oral antihyperglycaemic medications, provided effective and similar glucose control with similar safety profiles in patients with T2D.
Authors: Yazed AlRuthia; Ohud H Bahari; Suliman Alghnam; Ali M Alrumaih; Hassan Asiri; Mohammed Alshammari; Mansour Alhowimel; Hana A Al-Abdulkarim Journal: Front Public Health Date: 2022-06-13
Authors: Melanie J Davies; David A D'Alessio; Judith Fradkin; Walter N Kernan; Chantal Mathieu; Geltrude Mingrone; Peter Rossing; Apostolos Tsapas; Deborah J Wexler; John B Buse Journal: Diabetologia Date: 2018-12 Impact factor: 10.122
Authors: L L Ilag; M A Deeg; T Costigan; P Hollander; T C Blevins; S V Edelman; R J Konrad; R A Ortmann; R K Pollom; W J Huster; J S Zielonka; M J Prince Journal: Diabetes Obes Metab Date: 2016-01-08 Impact factor: 6.577
Authors: Helle Linnebjerg; Eric Chen Quin Lam; Xin Zhang; Mary E Seger; David Coutant; Laiyi Chua; Christoph Kapitza; Tim Heise Journal: Diabetes Obes Metab Date: 2016-09-08 Impact factor: 6.577
Authors: Liza L Ilag; Timothy M Costigan; Mark A Deeg; Robyn K Pollom; Curtis L Chang; Robert J Konrad; Melvin J Prince Journal: Diabetes Ther Date: 2017-03-30 Impact factor: 2.945